Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues.

scientific article published on 27 February 2009

Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.YMGME.2009.02.008
P698PubMed publication ID19307142

P50authorSharon ByersQ58055535
P2093author name stringDonald S Anson
Rachel Koldej
Jelena Lalic
Miriam Rothe
P2860cites workCorrection of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transferQ24534147
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingQ25938984
Gene transfer to human joints: progress toward a gene therapy of arthritisQ33853972
Arylsulfatase B-deficient mucopolysaccharidosis in ratsQ33893772
Prevalence of lysosomal storage disordersQ34489300
Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.Q35613015
Gene therapy for the treatment of musculoskeletal diseases.Q36236529
Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effectsQ36477567
NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic jointQ36803920
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.Q37363292
Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VIQ37396626
Mucopolysaccharidosis in a Cat with Arylsulfatase B Deficiency: A Model of Maroteaux-Lamy SyndromeQ39832785
Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale productionQ40396420
An improved beta-galactosidase reporter geneQ40596039
Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapyQ42099566
Helper plasmids for production of HIV-1-derived vectorsQ42822878
Rational development of a HIV‐1 gene therapy vectorQ42835119
Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr valuesQ42857331
In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectorsQ44016335
Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammationQ44869190
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).Q44883627
Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9.Q44912353
Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritisQ45623974
Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat.Q48200022
Long-term gene expression using the lentiviral vector in rat chondrocytes.Q50752002
In vivo gene delivery to synovium by lentiviral vectors.Q53974167
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Q63197223
Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4Q64380123
Clinical vignette. Mucopolysaccharidosis VI in a miniature pinscherQ70892008
Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the diseaseQ71762921
Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VIQ73843946
Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidosesQ74509531
Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VIQ80419661
Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and intervalQ82890246
P433issue2
P304page(s)102-108
P577publication date2009-02-27
P1433published inMolecular Genetics and MetabolismQ6895949
P1476titleLentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues
P478volume97

Reverse relations

cites work (P2860)
Q45874835Gene Delivery to Joints by Intra-articular Injection.
Q37994717Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases
Q37816955Getting arthritis gene therapy into the clinic
Q35367599Glycosaminoglycan storage disorders: a review
Q35173582IL-1RA gene-transfected bone marrow-derived mesenchymal stem cells in APA microcapsules could alleviate rheumatoid arthritis
Q30537079Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis
Q33713231Orthopedic gene therapy in 2008.
Q40608919Orthopedic gene therapy--lost in translation?
Q45858781Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy
Q43855295Rhodamine B and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose (F-GlcNAc) inhibit chondroitin/dermatan and keratan sulphate synthesis by different mechanisms in bovine chondrocytes
Q34545883Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).

Search more.